TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05120531

Intervention type: OTHER
Intervention: Monitoring patients undergoing surgery to look for association between ANS activity and bradycardia
Description: Use of an Ambulatory Monitoring System from Vuije University (VU-AMS) to record autonomic and cardiovascular activity of patients undergoing otolaryngologic surgery with anesthesia. This monitoring device will provide data of ANS activity and normoxic bradycardia among patients with Down Syndrome. This data will be compared to data from patients without Down Syndrome.

Intervention type: OTHER
Intervention: Monitoring patients undergoing surgery to look for association between ANS activity and bradycardia
Description: Use of an Ambulatory Monitoring System from Vuije University (VU-AMS) to record autonomic and cardiovascular activity of patients undergoing otolaryngologic surgery with anesthesia. This monitoring device will provide data of ANS activity and normoxic bradycardia among patients with Down Syndrome. This data will be compared to data from patients without Down Syndrome.
Study: NCT05980923

Intervention type: OTHER
Intervention: Performing blood thyroid test (TSH, FT4, FT3)
Description: Blood test as above

Intervention type: OTHER
Intervention: Performing blood thyroid test (TSH, FT4, FT3)
Description: Blood test as above
Study: NCT05098665

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Telemonitoring service
Description: Patients in the active arm will receive a cellular network connected set of digital scales, and instructed to take their weight each morning at the same time. This device (BodyTrace) automatically uploads each daily weight reading to a central database. A clinical algorithm is applied to detect those at risk of acute and subacute decompensated heart failure. Patients are contacted within 24-48 hours of being flagged as at risk by a heart failure specialist. A clinical history is taken, and medication review undertaken, in line with a protocol. Diuretics are adjusted as per the protocolised changes, or for patients at ceiling of treatment, referral for local specialist review is made. A third protocol for follow-up is then followed to close the loop of intervention.
Study: NCT05929196

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: In vitro full blood diagnostic test.
Description: Participant will donate approximately 5 ml blood sample. Later in a laboratory the sample will be processed in the microwave metamaterial sensor for non invasive blood glucose monitoring and standard biochemical analyzer. Specific dielectric properties and scattering parameters will be measured for blood glucose level determination.
Study: NCT05571644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI + Cadonilimab
Description: Cadonilimab（AK104）6mg/kg, intravenous d for 60 minutes, followed by mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycels before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOXIRI
Description: mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles before surgery
Study: NCT05803213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality 360 interactive video
Description: Clinical scenarios revised and presented with 360 video, and interactive design on the learning platform that is available anytime and anywhere to the medical students

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional mini-lecture
Description: Clinical scenario described according to the script as a mini-lecture to the medical students
Study: NCT05716256

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ulinastatin
Description: The CIS-ULI group received ulinastatin 5000U/kg followed by cisatracurium 0.1 mg/kg The CIS-NS (control) group received normal saline 0.1ml/kg followed by cisatracurium 0.1 mg/kg. The ROC-ULI group received ulinastatin 5000U/kg followed by rocuronium 0.6 mg/kg The ROC-NS (control) group received normal saline 0.1ml/kg followed by rocuronium 0.6 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Description: The CIS-ULI group received ulinastatin 5000U/kg followed by cisatracurium 0.1 mg/kg The CIS-NS (control) group received normal saline 0.1ml/kg followed by cisatracurium 0.1 mg/kg. The ROC-ULI group received ulinastatin 5000U/kg followed by rocuronium 0.6 mg/kg The ROC-NS (control) group received normal saline 0.1ml/kg followed by rocuronium 0.6 mg/kg

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: TOF monitoring
Description: The acceleromyograph TOF-Watch® SX (Organon, Ireland) is used for TOF monitoring. When the Narcotrend™ index is below 50 and level of anesthesia assessed as deep enough, TOF stimulation is started at 50 mA amplitudes and the setup is checked for any problem concerning the electrodes impedance and local hand temperature. After 1 minute, TOF stimulation is stopped and a tetanic stimulation (each electrical stimulus of 200μs duration and 50 mA amplitude) is delivered at a frequency of 50Hz for 5 seconds. After this procedure the alignment of sensors are checked to see if they are intact and readjust to their initial position if necessary. A no stimulation pause is observed during 3 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TOF monitoring
Description: The acceleromyograph TOF-Watch® SX (Organon, Ireland) is used for TOF monitoring. When the Narcotrend™ index is below 50 and level of anesthesia assessed as deep enough, TOF stimulation is started at 50 mA amplitudes and the setup is checked for any problem concerning the electrodes impedance and local hand temperature. After 1 minute, TOF stimulation is stopped and a tetanic stimulation (each electrical stimulus of 200μs duration and 50 mA amplitude) is delivered at a frequency of 50Hz for 5 seconds. After this procedure the alignment of sensors are checked to see if they are intact and readjust to their initial position if necessary. A no stimulation pause is observed during 3 minutes.
Study: NCT05451550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brachial plexus block
Description: An additional ultrasound-guided suprascapular nerve block(0.375% ropivacaine) were performed before general anesthesia induction in general anesthesia combined with brachial plexus block group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: General anesthesia were performed according to clinical routine: induction drugs: propofol, sufentanil, rocuronium, maintenance drugs: propofol, sevoflurane and remifentanil, Laryngeal mask ventilation.
Study: NCT05498077

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Body scan meditation
Description: Subject is placed through a brief body scan meditation to determine whether this intervention affects a person's pain experience
Study: NCT05195450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide fumarate
Description: • TAF 25 mg OD vs no treatment x 5 years and beyond
Study: NCT05451550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: General anesthesia were performed according to clinical routine: induction drugs: propofol, sufentanil, rocuronium, maintenance drugs: propofol, sevoflurane and remifentanil, Laryngeal mask ventilation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: General anesthesia were performed according to clinical routine: induction drugs: propofol, sufentanil, rocuronium, maintenance drugs: propofol, sevoflurane and remifentanil, Laryngeal mask ventilation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block
Description: An additional ultrasound-guided suprascapular nerve block(0.375% ropivacaine) were performed before general anesthesia induction in general anesthesia combined with brachial plexus block group
Study: NCT06074809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Guizhi Fuling granules
Description: Modified Guizhi Fuling granules will be orally administered to patients in the TCM treatment group twice a day throughout the treatment period, which lasts for 8 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be orally administered to patients in the placebo group twice a day throughout the treatment period, which lasts for 8 weeks.
Study: NCT04939012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPath Intervention
Description: MyPath is a novel patient-centered, reproductive planning decision support tool developed by the research team used to facilitate postpartum contraceptive decision-making among women with SUDs. Designed to facilitate high-quality decisions regarding pregnancy and contraception, MyPath helps women a) review their thoughts about pregnancy and children, b) learn about fertility and preconception health and c) prioritize their preferences for various contraceptive method characteristics (e.g. effectiveness, side effects). As such, MyPath uses a patient-centered approach to help women frame their contraceptive decisions in the context of their goals and health and is a critical first step towards addressing reproductive health inequities among women with SUDs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Standard of Care
Study: NCT04828265

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldafermin
Description: Single dose of aldafermin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldafermin
Description: Single dose of aldafermin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldafermin
Description: Single dose of aldafermin
Study: NCT05706844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: plain or heavy Bupivacaine hydrochloride 10 mg (2 mL) injected in the spinal canal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Description: Propofol (induction: 1.0-2.0 mg/kg. infusion: 3-5 mg/kg/hour) + Remifentanil (induction: 3-5 mcg/kg, infusion: 0.5 mcg/kg/min) given intravenously
Study: NCT06080880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron every 3 weeks
Description: Ondansetron, Po, 24mg/d, 3 days' application every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: aprepitant, Po, 125mg/d, 1day' application every 3 weeks
Study: NCT05648318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose oral solution
Description: In the LOS group, patients were instructed to drink 200ml lactulose (Duphalac, Olst, the Netherlands; 200ml/bottle) diluted with clear water into 1L 4-6h before colonoscopy at a rate of 250ml every 30min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG
Description: patient in the PEG group were instructed to drink 2L of PEG (each liter containing 59g PEG 4000, 1.46g sodium chloride, 5.68g sodium sulfate, 0.74g potassium chloride, 1.68g sodium bicarbonate; WanHe Pharmaceutical Co, Ltd., China) 4-6h before colonoscopy at a rate of 250ml every 15min
Study: NCT06080880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: aprepitant, Po, 125mg/d, 1day' application every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: dexamethasone, iv, 10mg/d, 1day' application every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: dexamethasone, iv, 10mg/d, 1day' application every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron weekly
Description: Ondansetron, Po, 24mg/d, 3 days' application weekly
Study: NCT05288894

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance imaging
Description: A routine cardiac magnetic resonance imaging with biventricular function evaluation, atrial volumes, LGE acquisitions, and pulmonary and aortic assesment.
Study: NCT06083727

Intervention type: OTHER
Intervention: rate of cesarean section
Description: rate of primary cesarean section in primigravida and multigravida

Intervention type: OTHER
Intervention: rate of cesarean section
Description: rate of primary cesarean section in primigravida and multigravida
Study: NCT05124834

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood glucose measurement, blood glucose monitor for personal use
Description: measurement of the blood glucose concentration using the blood glucose monitor for personal use (TJ100)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood glucose measurement, laboratory reference device
Description: measurement of the blood glucose concentration using a laboratory reference device (YSI 2300 Stat Plus)
Study: NCT06229704

Intervention type: DIAGNOSTIC_TEST
Intervention: video Head Impulse Test
Description: For v-HIT, the Synapsys v-HIT Ulmer device is used.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cervical Vestibular Evoked Myogenic Potential
Description: For cVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ocular Vestibular Evoked Myogenic Potential
Description: For oVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.

Intervention type: DIAGNOSTIC_TEST
Intervention: Computerized Dynamic Posturography
Description: To evaluate functional balance of the children and the relative contributions of the vision, proprioception, and vestibular system a CDP from Virtualis (Virtualis, Montpellier, France) is used.

Intervention type: OTHER
Intervention: Dizziness Handicap Inventory for patient caregivers
Description: DHI is a caregiver-reported 21- item questionnaire. It is designed to evaluate the perceived quality of life and handicap resulting from dizziness and unsteadiness for the pediatric population. For each question there are three possible answers: yes, sometimes or no. Each answer provides respectively 4, 2 and 0 points. The total DHI scores range from 0 to 84 with higher score being consistent with more limitation and more severe handicap. Scores under 16 are characterized as no limitation or handicap. A score from 16-26 present a mild perceived handicap and mild limitations. A DHI-score between 26-43 is classified as a moderate problem, and a score above 43 describes a severe perceived handicap and severe limitations.
Study: NCT06435780

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DIPRF
Description: Denuded interpositional pedicled rolled flap technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DIPRF
Description: Denuded interpositional pedicled rolled flap technique
Study: NCT05236413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Exercise
Description: Patients will be required to report for three sessions of supervised stationary cycling exercise per week over a period of 4-weeks. Training heart rates will be determined based on the pre-testing VO2peak and peak heart rate (PHR). All sessions will be supervised by trained personnel.~Patients will start with eight intervals of 2-min duration at 80-85% of PHR, separated by 2 min of recovery at 50% of PHR, progressing to four, 4-min intervals at 90-95% PHR, separated by 3 min at 50% PHR by the end of week 2.~Each training session will begin with a 10-min warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Subjects will be weighed prior to every exercise session and weight tracked to ensure that their volume status hasn't changed significantly. Subjects will be instructed to maintain usual levels of physical activity and usual diet during the study and not to make any modifications to the same.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Approaches to Stop Hypertension (DASH) Diet
Description: Patients will be interviewed with regard to their food/religious preferences and food allergies and a 7-day rotating meal plan will be designed per their preferences along with a registered dietitian. This will ensure that patients receive food that is acceptable to them. Participants will then be provided pre-packaged meals for 4-weeks with macronutrient compositions as follows - (Carbohydrates -55-60%, Protein -15-20%, Fat -15-25%, Fiber -35-45g/day). All foods will be labeled, sealed, and packed for weekly delivery and will be designed such that they can be refrigerated or frozen and stored without significant alterations to nutritional content. All food will be prepared by the UVA Hospital Nutrition Services department in conjunction with a registered dietician. Deviations (if any) from the study meal plan will be recorded by the participants in a food record provided at the start of each diet intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise + DASH Diet
Description: Patients will undergo both the exercise training intervention and DASH diet as explained above.
Study: NCT05115409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 Antibody Plus Chidamide and Rituximab
Description: Anti-PD-1 Antibody 200mg, ivd, D1, every 3 weeks Chidamide 30mg, po,D-1, 4, 8, 11, 15, 18, every 3 weeks Rituximab 375mg/m2, ivd, D1, every 3 weeks
Study: NCT05842460

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrient warning labels
Description: Inclusion of nutrient warning labels, which are currently mandatory in Brazil, to images of food products.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrient and ultraprocessed warning labels
Description: Inclusion of nutrient warning labels, which are currently mandatory in Brazil, and an experimental ultraprocessed warning label to images of food products.
Study: NCT04946955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application and website with or without promotion
Description: Development of an application and a website to de-stigmatise mental health and support the user in seeking help

Intervention type: OTHER
Group type: OTHER
Intervention: Application and website with or without promotion
Description: Development of an application and a website to de-stigmatise mental health and support the user in seeking help
Study: NCT04102436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg or 72,000 IU/kg (based on total body weight) IV over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sleeping Beauty Transposed PBL
Description: Day 0: Cells are to be infused at a dose not to exceed 1.5e11 in 400 mL intravenously on the Patient Care Unit over 20-30 minutes or as clinically determined by an investigator for patient safety (between 2-4 days after the last dose of fludarabine).
Study: NCT05761145

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Blood sample collection

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Blood sample collection

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Blood sample collection
Study: NCT05443087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling to build population pharmacokinetics model
Description: Determine for each drug plasmatic exposure (Css, trough) through the PopPK model.~Concentrations measured at the following time points:~* 1 month after the first treatment administration~* 2 months after the first treatment administration~* In case of progression~* In case of severe toxicities (AESI) related to the drug received

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling to build population pharmacokinetics model
Description: Determine for each drug plasmatic exposure (Css, trough) through the PopPK model.~Concentrations measured at the following time points:~* 1 month after the first treatment administration~* 2 months after the first treatment administration~* In case of progression~* In case of severe toxicities (AESI) related to the drug received

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling to build population pharmacokinetics model
Description: Determine for each drug plasmatic exposure (Css, trough) through the PopPK model.~Concentrations measured at the following time points:~* 1 month after the first treatment administration~* 2 months after the first treatment administration~* In case of progression~* In case of severe toxicities (AESI) related to the drug received

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling to build population pharmacokinetics model
Description: Determine for each drug plasmatic exposure (Css, trough) through the PopPK model.~Concentrations measured at the following time points:~* 1 month after the first treatment administration~* 2 months after the first treatment administration~* In case of progression~* In case of severe toxicities (AESI) related to the drug received
Study: NCT06431399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-2004 qd
Description: Group I(Peroid I-JLP-2004 FAST, Peroid II-JLP-2004 FED), Group II(Period I-JLP-2004 FED, Period II-JLP-2004 FAST)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-2004 qd
Description: Group I(Peroid I-JLP-2004 FAST, Peroid II-JLP-2004 FED), Group II(Period I-JLP-2004 FED, Period II-JLP-2004 FAST)
Study: NCT04810494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Lidocaine HCl topical solution
Description: 0.5mL of 2% Lidocaine will be administered intranasally in each nostril with a mucosal atomization device.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium chloride
Description: 0.5mL of 0.9% Sodium chloride (normal saline) will be administered intranasally in each nostril with a mucosal atomization device.